Programme | Speaker |
|---|---|
Welcome and introduction | Chair: Tadeusz Robak (Lodz, Poland) |
The burden of COVID-19 in patients with CLL | Lydia Scarfò (Milan, Italy) |
Unlocking the risk of infection in CLL with epidemiology, clinical observations and machine learning | Christian Brieghel (Copenhagen, Denmark) |
Uncovering patients’ infection risk in lymphoma and associated treatments including CAR-T cell therapy | Vincent Camus (Rouen, France) |
Real-world evidence leveraging the use of immunoglobulin replacement therapy in hematological malignancies | Fabrizio Vianello (Padua, Italy) |
Panel discussion – Q&A | All |
Closing | Tadeusz Robak (Lodz, Poland) |
Hybrid09/06/2022
EHA Congress
European Hematology Association
:quality(80)/f/54881/792x594/7f5735bbea/eha-2022-octapharma-symposium.jpg)
Join us for the 2022 edition of the European Hematology Association (EHA) Congress
Octapharma is supporting the #EHA2022 Hybrid Congress to keep the scientific community up to date on treating patients with secondary immunodeficiencies associated with hematological malignancies.
Octapharma Update-in-Hematology
Innovative approaches to reduce the infection burden in hematological malignancies
Friday 10th of June 18:00 - 19:00 CET
This scientific information may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities. This program was developed for use outside the U.S., is intended for non-U.S. HCPs, and is to be used in accordance with local laws and regulations.
Speakers panel
Chair: Tadeusz Robak
Copernicus Memorial Hospital
Medical University of Lodz, Poland
Lydia Scarfò
Vita-Salute San Raffaele
University of Milan, Italy
Christian Brieghel
Rigshospitalet, Copenhagen,
Denmark
Fabrizio Vianello
University of Padua,
Italy
Vincent Camus
Centre Henri Becquerel,
Rouen, France
Visit our website to learn more about SID
"Secondary immunodeficiencies have been a major concern in hematological malignancies. We need to remain very careful with the risk of infection.", says Dr. Anne Quinquenel (Reims, France).
Discover more on hematological malignancies
Octapharma's exclusive educational platform for healthcare professionals.